Growth Metrics

Pfizer (PFE) Non-Current Assets (2016 - 2025)

Pfizer (PFE) has disclosed Non-Current Assets for 17 consecutive years, with $165.3 billion as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Assets rose 5027.58% to $165.3 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $234.8 billion, a 7184.33% increase, with the full-year FY2025 number at $165.3 billion, up 5027.58% from a year prior.
  • Non-Current Assets was $165.3 billion for Q4 2025 at Pfizer, up from -$46.9 billion in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $178.2 billion in Q2 2024 to a low of -$46.9 billion in Q3 2025.
  • A 5-year average of $62.0 billion and a median of $35.2 billion in 2022 define the central range for Non-Current Assets.
  • Biggest YoY gain for Non-Current Assets was 5027.58% in 2025; the steepest drop was 126.62% in 2025.
  • Pfizer's Non-Current Assets stood at $3.6 billion in 2021, then decreased by 15.41% to $3.0 billion in 2022, then decreased by 0.17% to $3.0 billion in 2023, then grew by 7.11% to $3.2 billion in 2024, then soared by 5027.58% to $165.3 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Non-Current Assets are $165.3 billion (Q4 2025), -$46.9 billion (Q3 2025), and $162.3 billion (Q2 2025).